Key result
Nicotinic acid and estrogens rank among the few therapies consistently altering plasma Lp(a) levels.
Answers are grounded in this paper and cite their sources.
Lipoprotein (a) has been implicated with an increased risk of atherosclerosis and cardiovascular disease. Recently, considerable progress has been made toward understanding the importance of genetics in the regulation of plasma levels of lipoprotein (a). However, the issue as to whether lipoprotein (a) levels should be treated is still debated and furthermore the possibilities to influence lipoprotein (a) levels remain limited. The potential clinical importance of lipoprotein (a) has stimulated interest in the dietary and pharmacologic agents that affect this lipoprotein. At present, only a few of the existing therapeutic tools, such as nicotinic acid and estrogens, have been found to consistently affect lipoprotein (a).
No takes yet. Share an insight, caveat, or question.
Lars Berglund (1995) conducted a review in Elevated lipoprotein (a) and cardiovascular disease risk. Diet and pharmacologic agents (e.g., nicotinic acid, estrogens) was evaluated on Plasma levels of lipoprotein (a). Dietary and pharmacologic agents, such as nicotinic acid and estrogens, are among the few existing therapies found to consistently affect plasma lipoprotein (a) levels.
Synapse has enriched 10 related papers. Consider them for comparative context: